MOUNTAIN VIEW, Calif., March 5, 2013 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced a new program offering eligible patients a discount on Qsymia ® (phentermine and topiramate extended-release) capsules CIV for a limited time. The Save Now! Program is available online exclusively at www.qsymia.com and provides patients with the opportunity to pay no more than $75 for 30 days of the recommended dose (Qsymia 7.5 mg/46 mg). This represents up to $85 savings off the full retail price (which may vary by pharmacy) for this once daily therapy.
"We believe our Qsymia offer programs provide more patients struggling with obesity the opportunity to partner with their physicians to experience the benefits of Qsymia," said Peter Y. Tam, president of VIVUS. "Our goal is to take every measure to make Qsymia more accessible to patients today as we continue to make progress toward achieving reimbursement for patients who qualify."
Qsymia is the only FDA-approved once daily combination therapy – and the first medication available in 13 years – for chronic weight management.
To obtain the offer, patients must have a valid prescription issued by a physician. The offer is limited to one per patient for the duration of the program. Patients who qualify for the offer program are eligible to receive 30 days of the recommended dose (7.5 mg/46 mg) of Qsymia once daily for no more than $75.It is suggested that new patients initiate therapy on the Qsymia starting dose of 3.75 mg/23 mg for 14 days and then increase to the Qsymia recommended dose of 7.5 mg/46 mg. This new offer complements the Qsymia Get Started! Free Trial Program, which provides eligible patients a free trial on a valid prescription for up to 14 capsules of the Qsymia starting dose (3.75 mg/23 mg). For more information, visit www.qsymia.com. * Based on the full retail price of 30 capsules of Qsymia 7.5 mg/46 mg ( $85 savings), and the full retail price of 14 capsules of the Qsymia starting dose, 3.75 mg/23 mg ( $65 savings), for a total of $150. About Qsymia Qsymia is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol. The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts